II
Immunis, Inc.
SEC filingBiotechnology · Irvine, CA
Amount raised$12Msold at filing
Total offering$12M
Investors in the raise12count reported to the SEC
FiledJun 15, 2026first sale May 28, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Takahide KodaDirector
Hans KeirsteadExecutive Officer, Director
Daniel KraftDirector
Gabriel NistorExecutive Officer
Executive officers, directors and promoters as listed on the Form D.